Literature DB >> 27873212

HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.

S Cantara1, C Marzocchi2, M G Castagna2, F Pacini2.   

Abstract

INTRODUCTION: Thyroid cancer may have a familial predisposition and may occur in the context of hereditary syndromes or as isolated tumor. Recently, the G534E variant in the HABP2 gene has been suggested as causative mutation for familial thyroid cancer, but other studies gave contradictory results.
METHODS: We have analyzed the G534E variant in an Italian series of 63 familial thyroid cancer patients and 41 unaffected family members with end-point PCR, DHPLC and direct sequencing.
RESULTS: All samples analyzed displayed a pattern typical of the homozygous wild type revealing the absence of the G534E variant.
CONCLUSION: In this study, HABP2 G534E variant is not correlated with the familial form of PTC.

Entities:  

Keywords:  Familial non-medullary thyroid cancer; G534E; HABP2; Italian population; Thyroid cancer

Mesh:

Substances:

Year:  2016        PMID: 27873212     DOI: 10.1007/s40618-016-0583-9

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  7 in total

1.  HABP2 in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?

Authors:  Joanne Ngeow; Charis Eng
Journal:  J Natl Cancer Inst       Date:  2016-02-01       Impact factor: 13.506

2.  Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer.

Authors:  Silvia Cantara; Milena Pisu; Daniela Virginia Frau; Paola Caria; Tinuccia Dettori; Marco Capezzone; Serena Capuano; Roberta Vanni; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

3.  HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.

Authors:  Ali S Alzahrani; Avaniyapuram Kannan Murugan; Ebtesam Qasem; Hindi Al-Hindi
Journal:  Thyroid       Date:  2016-04-08       Impact factor: 6.568

4.  Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Authors:  R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei
Journal:  J Endocrinol Invest       Date:  2016-08-17       Impact factor: 4.256

5.  Rare diseases in clinical endocrinology: a taxonomic classification system.

Authors:  G Marcucci; L Cianferotti; P Beck-Peccoz; M Capezzone; F Cetani; A Colao; M V Davì; E degli Uberti; S Del Prato; R Elisei; A Faggiano; D Ferone; C Foresta; L Fugazzola; E Ghigo; G Giacchetti; F Giorgino; A Lenzi; P Malandrino; M Mannelli; C Marcocci; L Masi; F Pacini; G Opocher; A Radicioni; M Tonacchera; R Vigneri; M C Zatelli; M L Brandi
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

6.  Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer.

Authors:  Silvia Cantara; Serena Capuano; Caterina Formichi; Milena Pisu; Marco Capezzone; Furio Pacini
Journal:  Thyroid Res       Date:  2010-08-11

7.  HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.

Authors:  Alexia L Weeks; Scott G Wilson; Lynley Ward; Jack Goldblatt; Jennie Hui; John P Walsh
Journal:  BMC Med Genet       Date:  2016-08-17       Impact factor: 2.103

  7 in total
  9 in total

Review 1.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

2.  Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls.

Authors:  Laure Cazabat; Aglae Terray; Philippe de Mazancourt; Jacques Ropers; Lionel Groussin; Marie-Laure Raffin-Sanson
Journal:  Eur Thyroid J       Date:  2017-06-23

3.  Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.

Authors:  Chen-Tian Shen; Guo-Qiang Zhang; Zhong-Ling Qiu; Hong-Jun Song; Zhen-Kui Sun; Quan-Yong Luo
Journal:  Endocrine       Date:  2019-03-02       Impact factor: 3.633

4.  Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.

Authors:  Ying Jiang; Jinfeng Li; Cuiqin Sang; Guangming Cao; Shuzhen Wang
Journal:  Ann Transl Med       Date:  2020-09

5.  Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.

Authors:  Valentina Cirello; Carla Colombo; Olga Karapanou; Gabriele Pogliaghi; Luca Persani; Laura Fugazzola
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-07       Impact factor: 5.555

Review 6.  Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Authors:  José Manuel Cameselle-Teijeiro; Ozgur Mete; Sylvia L Asa; Virginia LiVolsi
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 3.943

Review 7.  Genetic susceptibility to hereditary non-medullary thyroid cancer.

Authors:  Tina Kamani; Parsa Charkhchi; Afshan Zahedi; Mohammad R Akbari
Journal:  Hered Cancer Clin Pract       Date:  2022-03-07       Impact factor: 2.857

8.  Pitfalls of exome sequencing: a case study of the attribution of HABP2 rs7080536 in familial non-medullary thyroid cancer.

Authors:  Glenn S Gerhard; Darrin V Bann; James Broach; David Goldenberg
Journal:  NPJ Genom Med       Date:  2017-03-28       Impact factor: 8.617

Review 9.  Familial non-medullary thyroid cancer: a critical review.

Authors:  M Capezzone; E Robenshtok; S Cantara; M G Castagna
Journal:  J Endocrinol Invest       Date:  2020-10-06       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.